RegenMedTX Overview
- Founded
-
2014
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
RegenMedTX General Information
Description
Developer of cell therapies for chronic kidney disease. The company develops cell therapy products that are programmed in the body to restore damaged kidney tissues by engrafting into, repairing or replacing damaged tissues or organ.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 3929 Westpoint Boulevard
- Suite G
- Winston-Salem, NC 27103
- United States
+1 (336) 000-0000
RegenMedTX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 01-Mar-2016 | 00.000 | Completed | Startup | ||
| 1. Seed Round | 05-Aug-2015 | 00.000 | 00.000 | Completed | Startup |
RegenMedTX Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cell therapies for chronic kidney disease. The company develops cell therapy products that are programmed i
Biotechnology
Winston-Salem, NC
00.000
000000&0
00.000
000000
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cul
0000 000000000
Ann Arbor, MI
00
As of 0000
00000
000000 - 000
00000
000000
empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitatio
0000 000000000
Oslo, Norway
00
As of 0000
00000000000
Add Comparison
RegenMedTX Competitors (3)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lycera | Venture Capital-Backed | Ann Arbor, MI | 00 | 00000 | 000000 - 000 | 00000 |
| 0000000 | Venture Capital-Backed | Oslo, Norway | 00 | 00000000000 | ||
| 0000000 | Formerly VC-backed | Waltham, MA | 000 | 00000 | 000000 - 000 | 00000 |
RegenMedTX Patents
RegenMedTX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20160101133-A1 | Organoids comprising isolated renal cells and use thereof | Pending | 08-May-2013 | 000000000 | 00 |
| CA-2911291-A1 | Organoids comprising isolated renal cells and uses thereof | Pending | 08-May-2013 | 000000000 | |
| AU-2014262670-A1 | Organoids comprising isolated renal cells and uses thereof | Granted | 08-May-2013 | 000000000 | |
| AU-2014262670-B2 | Organoids comprising isolated renal cells and uses thereof | Active | 08-May-2013 | 0000000000 | 0 |
| AU-2020203860-A1 | Organoids comprising isolated renal cells and uses thereof | Pending | 08-May-2013 | C12N5/0697 |
RegenMedTX Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Deepak Jain Ph.D | Chief Operating Officer |
RegenMedTX Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Kim Westmoreland | Self | Board Member | 000 0000 |
| William Hawkins III | Self | Chairman | 000 0000 |
RegenMedTX Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 01-Nov-2017 | 000000000 | Biotechnology | ||
| Tengion | 06-Mar-2015 | Merger/Acquisition | 000.00 | Biotechnology |